United Therapeutics (UTHR) CEO Rothblatt Sells $5.1M of Stock
Key Points
- Chairperson and CEO Martine Rothblatt sold 9,500 shares of United Therapeutics Corporation on October 16, 2026, under a pre-arranged plan.
- After the trade, Martine A Rothblatt indirectly holds 324,443 $UTHR shares, down 2.84% from before the trade.
- The stock recently traded around $543.15, sitting up about 1.9% from its close of $533.12 on the day of the transaction.
- The company heads toward its next financial update scheduled for October 28, 2026.
Since the trade, $UTHR is up 1.3% to date (from the $533.12 close on Oct 16, 2026).
Get United Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $UTHR.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated United Therapeutics Corporation alert may contain errors. Disclosures
United Therapeutics Corporation Chairperson and CEO Martine Rothblatt sold 9,500 shares of stock on October 16, 2026, for a total value of about $5.1 million. The transaction was revealed in a Form 4 filing with the Securities and Exchange Commission. The planned sale took place at an average price of $534.66 per share. Following this transaction, Rothblatt held 324,443 shares, representing a 2.84% drop in her personal holding.
UTHR
United Therapeutics Corporation
Other Institutional Activity in United Therapeutics Corporation
Large investment firms made adjustments to their stakes earlier in the year. Avoro Capital Advisors LLC grew its holdings by 147,804 shares, ending with 2,777,777 shares worth about $1.51 billion. Renaissance Technologies, LLC reduced its stake by 78,271 shares, finishing with 1,708,739 shares valued at roughly $928.1 million. Jupiter Topco LLC doubled its investment by adding 415,564 shares to hold 831,129 shares worth about $451.4 million.
United Therapeutics Corporation Stock Up 0.3%
The stock recently traded around $543.15 as of October 19, 2026, putting it up about 1.9% since it closed at $533.12 on the trade date. The biotech firm carries a low beta of 0.49, meaning it tends to move less than the broader market.
Recent Earnings
United Therapeutics reported trailing twelve month revenue of $3.15 billion and earnings of $27.92 per share. The biotech firm posted a net margin of 41.6% and a return on equity of 19.3%. The company is scheduled to report its next financial results on October 28, 2026.
Insider Buying and Selling at United Therapeutics Corporation
Insiders have been active with planned transactions. Rothblatt sold 9,500 shares on October 12 for about $5.2 million, another 9,500 shares on October 13 for about $5.2 million, and 9,500 shares on October 15 for about $5.2 million. EVP and General Counsel Paul A. Mahon sold 8,300 shares on October 15 for about $4.5 million.
Analysts Set New Price Targets
Wall Street firms updated their views ahead of upcoming earnings. RBC Capital maintained an outperform rating with a $708 target on October 8. Morgan Stanley kept an equal-weight rating and a $566 target on October 7. BTIG upgraded the stock to a buy with a $728 target on October 1. Goldman Sachs initiated coverage with a sell rating and a $321 target on September 24. RBC Capital previously maintained an outperform rating with a $677 target on August 6.
About United Therapeutics Corporation
Headquartered in Silver Spring, Maryland, United Therapeutics develops and sells medical products focused on chronic and life-threatening conditions. The company works on specialty pharmaceuticals to address significant unmet medical needs for patients globally.
Bottom Line
Investors will watch for the upcoming earnings report on October 28, 2026, for further financial updates. Form 4 filings will continue to show whether executives maintain their selling pace under pre-arranged trading plans.
Related Filing Alerts
Source: Martine A Rothblatt's Form 4 filing on $UTHR (Oct 16, 2026). Written by software, not financial advice. How we make alerts